AtaiBeckley Inc. (ATAI) Stock
ATAI has an Alpha Score of 23 out of 100 (poor), computed on Nov 9, 2026 from 2 of 4 sub-scores.
What is ATAI's Alpha Score?
How it works →Alpha Score of 23 reflects poor overall profile with poor momentum, moderate quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 9, 2026
A rules-based research rating, not a recommendation to buy or sell.
What are ATAI's key statistics?
Key statistics as of Nov 9, 2026
ATAI price chart
Powered by TradingViewWhat does AtaiBeckley Inc. do?
AtaiBeckley Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative psychedelic-based therapeutics and neuroplastogens to treat mental health disorders. The company was formed through the strategic combination of atai Life Sciences and Beckley Psytech Limited in November 2025. AtaiBeckley focuses on addressing significant unmet medical needs in psychiatry, particularly in treatment-resistant depression, social anxiety disorder, and other psychiatric conditions where traditional therapies have proven ineffective. The company's pipeline includes multiple candidates across various delivery modalities, including intranasal sprays, oral transmucosal films, and oral tablets. Operating at the intersection of psychedelic science and neuropharmacology, AtaiBeckley develops rapid-acting, convenient mental health treatments designed to transform patient outcomes. Founded in 2018 and headquartered in Berlin, Germany, the company maintains operations across the United States, Germany, and Canada, combining expertise in drug development, healthcare, and commercialization to advance breakthrough mental health therapies.